IRIS Institutional Research Information System - OPENBS Open Archive UniBS

TORTI, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.935
EU - Europa 3.510
AS - Asia 2.149
OC - Oceania 16
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 9
AF - Africa 7
Totale 15.639
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.909
CN - Cina 1.406
UA - Ucraina 1.403
DE - Germania 699
IT - Italia 398
HK - Hong Kong 365
FI - Finlandia 335
GB - Regno Unito 233
IE - Irlanda 221
SG - Singapore 214
IN - India 114
FR - Francia 96
RU - Federazione Russa 38
SE - Svezia 31
BE - Belgio 23
CA - Canada 20
TR - Turchia 19
IR - Iran 16
AU - Australia 15
BR - Brasile 10
CZ - Repubblica Ceca 10
EU - Europa 9
NL - Olanda 9
JP - Giappone 4
MU - Mauritius 4
MX - Messico 4
HU - Ungheria 3
ID - Indonesia 3
AR - Argentina 2
EG - Egitto 2
ES - Italia 2
MS - Montserrat 2
PL - Polonia 2
AM - Armenia 1
AT - Austria 1
BD - Bangladesh 1
BY - Bielorussia 1
CH - Svizzera 1
CY - Cipro 1
EC - Ecuador 1
KR - Corea 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MD - Moldavia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
TN - Tunisia 1
Totale 15.639
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.410
Fairfield 1.409
Jacksonville 1.031
Houston 868
Ann Arbor 704
Ashburn 670
Cambridge 615
Seattle 602
Wilmington 568
Chandler 431
Princeton 411
Nanjing 393
Hong Kong 364
Dublin 221
Beijing 159
Nanchang 147
Helsinki 129
Singapore 108
New York 105
Des Moines 100
San Diego 96
Hebei 92
Shenyang 89
Changsha 83
Jinan 63
Tianjin 63
Lancaster 62
Jiaxing 58
Shanghai 53
Dearborn 51
Milan 51
Kunming 39
Hangzhou 34
Verona 34
Brescia 26
Los Angeles 25
Brussels 23
San Francisco 20
Ningbo 19
Toronto 18
Boardman 17
London 17
Ardabil 16
Lanzhou 16
Zhengzhou 16
Washington 15
Kocaeli 13
Changchun 12
Norwalk 12
Haikou 10
Orange 10
Taizhou 10
Brno 9
Guangzhou 9
Taiyuan 9
Augusta 8
Melbourne 8
Belo Horizonte 7
Nürnberg 7
Rome 7
Auburn Hills 6
Hanover 6
Leawood 6
Monmouth Junction 6
Pune 6
Lappeenranta 5
Palermo 5
Redwood City 5
Carate Brianza 4
Kilburn 4
Chicago 3
Chiswick 3
Fuzhou 3
Pavia 3
Phoenix 3
Redmond 3
San Mateo 3
Spilamberto 3
Sydney 3
São Paulo 3
Vicenza 3
Walnut 3
Ambrogio 2
Amsterdam 2
Avellino 2
Bollate 2
Budapest 2
Como 2
Dallas 2
Fano 2
Florence 2
Gunzenhausen 2
Indiana 2
Mantova 2
Naples 2
Napoli 2
Perth 2
Prescot 2
Quartu Sant'elena 2
Santa Clara 2
Totale 11.797
Salva come PNG Salva come JPEG
Nome #
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. 259
The Disagreement Among Methods to Evaluate Glomerular Filtration Rate in HIV-Infected Patients Naive to Antiretroviral Therapy. 190
The evolving burden of HIV infection compared with other chronic diseases in northern Italy 152
Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection 142
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 136
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy 135
Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy 130
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 122
HIV-associated asymmetric lipodystrophy syndrome 121
Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons 120
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. 118
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. 118
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. 117
Key Questions in antiretroviral therapy: Italian Consensus Workshop (2005) 116
Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report. 115
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study. 115
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy 115
Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting 113
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: Routine evidence from the Italian MASTER Cohort 112
Bcl-2 expression is moderately correlated with long-term variability of CD4+ T-cell increase under successful highly active antiretroviral therapy 109
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. 108
Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study 107
The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool 107
Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications. 105
Virological effectiveness and CD4+ T-cell increase over early andlate courses in HIV infected patients on antiretroviral therapy: focus on HCV andanchor class received 104
All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration  103
HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir containing regimens 102
Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target? 102
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. 102
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the “COPA” pilot randomized trial 101
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations 100
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART 100
Polymorphic immune restoration syndrome after effective HAART 99
Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response 99
Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide 98
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 98
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. 98
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy 98
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 98
Impact of detectable human cytomegalovirus DNAemia on viro-immunologicaleffectiveness of HAART in HIV-infected patients naive to antiretroviral therapy 97
CD4+ T cell evolution and predictors of its trend before and aftertenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 96
Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART) 96
Risk factors for myocardial infarction in HIV positive patients 95
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48 week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial 94
First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006). 94
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. 94
Towards HCV extinction with modern HCV treatment? “Yes we can!” 94
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study 94
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. 94
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction 93
Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy). 93
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations 93
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina 92
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study 92
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 91
Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. 91
Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis 91
The Impact of Gender and Anchor Drugs on TDF Renal Toxicity 91
Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone. 90
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI 90
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort 89
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts 89
I data-base clinici e la sorveglianza degli eventi avversi: il progetto MASTER 88
A king in the CASTLE? Optimum initial HIV protease inhibitor. 88
Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes 88
Long-term immunological benefit in patients with discordant responses to therapy depends on both level of viremia and duration of rebound 87
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts 87
Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. 86
Potential role of SEN virus on liver enzyme abnormalities in patients positive for hepatitis C virus with or without HIV infection. 86
Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors 86
HIV/HTLV co-infection: frequency and epidemiological characteristics among patients admitted to an Italian hospital 86
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count 86
Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch 86
Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors. 85
HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure 85
Natural history of chronic hepatitis B in co-infected patients. 84
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 84
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies 84
Risk of triple-class virological failure in children with HIV: a retrospective cohort study 84
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years 83
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures 83
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads 83
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis 83
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations. 83
Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission 83
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study. 83
Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients 83
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. 82
The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions 82
Screening and Management of HIV-2-Infected Individuals in Northern Italy. 81
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. 81
Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study. 80
Increasing clinical virulence in two decades of the Italian HIV epidemic 80
Genetic polymorphisms differently influencing the emergence of atrophy and fataccumulation in HIV-related lipodystrophy 80
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE) 80
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal 79
Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008 79
No evidence of benefical effect of GB virus type C infection on the course of HIV infection. 78
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. 78
The use of ultrasonography, transient elestography, APRI and FIB-4 to measure liver steatosis and fibrosis in HIV-positive patients not co-infected with hepatitis viruses with hypertransaminasemia of unknown origin on HAART 78
Totale 9.879
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.546
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.546
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.644 0 0 141 630 257 483 393 493 333 546 88 280
2020/20212.767 42 324 59 337 105 348 135 394 421 251 265 86
2021/20221.477 76 275 7 89 5 87 61 98 69 195 141 374
2022/20231.374 225 18 11 83 131 416 0 129 228 15 44 74
2023/20241.164 74 24 67 114 46 172 35 32 372 14 15 199
2024/202538 28 10 0 0 0 0 0 0 0 0 0 0
Totale 15.794